Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.

Christine G KohnThomas J BunzJan Beyer-WestendorfCraig I Coleman

Published in: European journal of haematology (2018)

Rivaroxaban was associated with a reduced risk of overall, gastrointestinal, and intracranial major bleeding vs warfarin in unprovoked VTE. No bleeding subtype was significantly more frequent in rivaroxaban patients.

Keyphrases

venous thromboembolism
direct oral anticoagulants
atrial fibrillation
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
patient reported outcomes
oral anticoagulants
optic nerve